Oncology Peer Review On-The-Go: Molecular Profiling in Metastatic Colorectal Cancer
CancerNetwork examines a review article in the September issue of the journal ONCOLOGY discussing precision medicine and molecular profiling for patients with metastatic colorectal cancer.
This episode of "Oncology Peer Review On-The-Go" examines a review article published in the September issue of the journal ONCOLOGY. The article, “Molecular Profiling in Metastatic Colorectal Cancer,” was written by Samantha Armstrong, MD, Rita Malley, MS, and Benjamin Weinberg MD.
The piece discusses the epidemiology, tumor location, and mutational landscape of metastatic colorectal cancer. For an in-depth evaluation of that piece, CancerNetwork spoke with Armstrong and Weinberg from the Georgetown Lombardi Comprehensive Cancer Center.
For the article’s response perspective, CancerNetwork spoke with John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center. Dr. Marshall discussed the cost, quality of care, accessibility and more regarding molecular profiling and precision medicine.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
